A multispectral 3D live organoid imaging platform to screen probes for fluorescence guided surgery

Achieving complete tumor resection is challenging and can be improved by real-time fluorescence-guided surgery with molecular-targeted probes. However, pre-clinical identification and validation of probes presents a lengthy process that is traditionally performed in animal models and further hampere...

Descripción completa

Detalles Bibliográficos
Autores: Jeremiasse, Bernadette, Ineveld, Ravian L. van, Bok, Veerle, Kleinnijenhuis, Michiel, Blank, Sam de, Alieva, María, Johnson, Hannah R., Vlie, Esmée J. van, Zeeman, Amber L., Wellens, Lianne M., Llibre-Palomar, Gerard, Barrera Román, Mario, Maggio, Alessia Di, Dekkers, Johanna F., Oliveira, Sabrina, Vahrmeijer, Alexander L., Molenaar, Jan J., Wijnen, Marc HWA, Steeg, Alida FW van der, Wehrens, Ellen J., Ríos, Anne C.
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/382720
Acceso en línea:http://hdl.handle.net/10261/382720
Access Level:acceso abierto
Palabra clave:Fluorescence-guided Surgery
Patient-derived Organoids
Multi-spectral 3D Imaging
Neuroblastoma
Breast Cancer
Descripción
Sumario:Achieving complete tumor resection is challenging and can be improved by real-time fluorescence-guided surgery with molecular-targeted probes. However, pre-clinical identification and validation of probes presents a lengthy process that is traditionally performed in animal models and further hampered by inter- and intra-tumoral heterogeneity in target expression. To screen multiple probes at patient scale, we developed a multispectral real-time 3D imaging platform that implements organoid technology to effectively model patient tumor heterogeneity and, importantly, healthy human tissue binding.

Similares en LA Referencia